Christine N. Spencer
A5102845921- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Ferroptosis and cancer prognosis
- CAR-T cell therapy research
- Immune cells in cancer
- Immune Cell Function and Interaction
- Diabetes and associated disorders
- Radiomics and Machine Learning in Medical Imaging
- Inflammatory Biomarkers in Disease Prognosis
- Ocular Oncology and Treatments
- Nanoplatforms for cancer theranostics
- Advanced Biosensing Techniques and Applications
- Complement system in diseases
- Retinal Imaging and Analysis
- Molecular Biology Techniques and Applications
- Retinal Diseases and Treatments
- Biosimilars and Bioanalytical Methods
Parker Institute for Cancer Immunotherapy
2023
The University of Texas MD Anderson Cancer Center
2015-2018
University of California, Santa Barbara
2011
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features pretreatment tumor biopsies have been reported to correlate with response patients melanoma other cancers, but robust biomarkers identified. We studied cohort of metastatic initially treated cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) (n = 53) followed by programmed death-1 (PD-1) at progression 46), analyzed signatures longitudinal tissue...
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms resistance remain incompletely understood. To address this, we recently studied a cohort melanoma patients treated with sequential against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) identified immune markers resistance. Building on these studies, performed deep molecular profiling including cell receptor...
Immune checkpoint inhibitors (ICIs), including CTLA-4- and PD-1-blocking antibodies, can have profound effects on tumor immune cell infiltration that not been consistent in biopsy series reported to date. Here, we analyze seven molecular datasets of samples from patients with advanced melanoma (N = 514) treated ICI agents investigate clinical, genomic, transcriptomic features anti-PD-1 response cutaneous melanoma. We find prior anti-CTLA-4 therapy is associated differences individual gene,...
We introduce a human retinal pigmented epithelial (RPE) cell-culture model that mimics several key aspects of early stage age-related macular degeneration (AMD). These include accumulation sub-RPE deposits contain molecular constituents drusen, and activation complement leading to formation deposit-associated terminal complexes. Abundant are rich in apolipoprotein E (APOE), prominent drusen constituent, formed by RPE cells grown on porous supports. Exposure serum results selective,...
Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response not been thoroughly elucidated. To better understand this, we studied a large cohort melanoma patients treated with targeted therapy or checkpoint blockade (n = 60). Heterogeneity therapeutic responses via radiologic assessment was observed majority patients. Synchronous metastases were analyzed deep profiling, revealed substantial all studied, considerable...
We have made major advances in the treatment of melanoma through use targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing sequence therapy. There is a growing appreciation impact antitumor responses to these therapies, we performed studies test hypothesis that clinical patterns infiltrates differ at progression on treatments. observed rapid kinetics patients compared blockade. To gain insight into possible mechanisms behind...
The low response rates to immunotherapy in uveal melanoma (UM) sharply contrast with reputable cutaneous (CM) patients. To characterize the mechanisms responsible for resistance UM, we performed immune profiling tumors from 10 metastatic UM patients and CM by immunohistochemistry (IHC). Although there is no difference infiltrating CD8+ T cells between CM, a significant decrease programmed death-1 (PD-1)-positive lymphocytes was observed lower levels of death ligand-1 (PD-L1) metastases...
Medical research for human benefit is greatly impeded by the necessity tissues and subjects. However, upon obtaining consent specimens, precious samples must be handled with greatest care in order to ensure integrity of organs, tissues, cells highest degree. Unfortunately, tissue processing definition requires extraction from host, a change which can cause great cellular stress have major repercussions on subsequent analyses. These stresses could result specimen being no longer...
Meeting abstracts Despite recent advances in the treatment of metastatic melanoma through targeted and immunotherapy, majority patients do not achieve a durable response. Research efforts to better understand responses are underway, numerous molecular mechanisms resistance
9575 Background: Although both targeted and immune therapies have significantly improved outcomes for mm pts, only a minority of pts experience durable responses with many multiple SMM demonstrating differential to therapy. We performed multidimensional spatial characterization markers in from patients treated improve our understanding correlations determinants response. Methods: NanoString's Digital Spatial Profiling research platform was used on 6 3 (treatment-naïve; BRAF + MEK therapy...
<p>Supplementary Figure Legends</p>
<p>Supplementary Figure 1. Immune profiling of pre-treatment, on-treatment and progression CTLA-4 blockade samples by immunohistochemistry. Supplementary 2. Myeloid cell 3. Increased contact between CD8 T cells CD68 myeloid in non-responding patients to anti-CTLA-4 anti-PD-1 therapy at pre-treatment blockade, PD-1 time points. 4. pre anti-PD-1, 5. Longitudinal increase CD8, PD-1, PD-L1 expression responders therapy. 6. Relative infiltrate tumor center on treatment. 7. Significant...
<p>Supplementary Figure 1. Immune profiling of pre-treatment, on-treatment and progression CTLA-4 blockade samples by immunohistochemistry. Supplementary 2. Myeloid cell 3. Increased contact between CD8 T cells CD68 myeloid in non-responding patients to anti-CTLA-4 anti-PD-1 therapy at pre-treatment blockade, PD-1 time points. 4. pre anti-PD-1, 5. Longitudinal increase CD8, PD-1, PD-L1 expression responders therapy. 6. Relative infiltrate tumor center on treatment. 7. Significant...
<p>Supplementary Figure Legends</p>
<div>Abstract<p>Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features pretreatment tumor biopsies have been reported to correlate with response patients melanoma other cancers, but robust biomarkers identified. We studied cohort of metastatic initially treated cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) (<i>n</i> = 53) followed by programmed death-1 (PD-1) at progression...
<div>Abstract<p>Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features pretreatment tumor biopsies have been reported to correlate with response patients melanoma other cancers, but robust biomarkers identified. We studied cohort of metastatic initially treated cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) (<i>n</i> = 53) followed by programmed death-1 (PD-1) at progression...